TY - JOUR
T1 - The Cross-sectional and longitudinal associations between il-6, il-10, and TNFα and cognitive outcomes in the mayo clinic study of aging
AU - Wennberg, Alexandra M.V.
AU - Hagen, Clinton E.
AU - Machulda, Mary M.
AU - Knopman, David S.
AU - Petersen, Ronald C.
AU - Mielke, Michelle M.
N1 - Funding Information:
This work was supported by the National Institutes of Health/National Institute on Aging grants (U01 AG006786)
Funding Information:
This work was supported by the National Institutes of Health/National Institute on Aging grants (U01 AG006786, R01 AG011378, R01 AG041851, P50 AG44170, RF1 AG55151, and R01 AG049704); the Robert H. and Clarice Smith and Abigail van Buren Alzheimer’s Disease Research Program, and was made possible by the Rochester Epidemiology Project (R01 AG034676).
Funding Information:
A.M.V.W. and C.E.H. have no disclosures to report. M.M.Ma. receives research support from the National Institutes of Health (U01 AG006786). R.O.R. receives research support from the National Institutes of Health (U01 AG006786) and an unrestricted research grant from F. Hoffman-La Roche. D.S.K. served as Deputy Editor for Neurology®; serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study; is an investigator in clinical trials sponsored by TauRx Pharmaceuticals, Lilly Pharmaceuticals and the Alzheimer’s Disease Cooperative Study; and receives research support from the NIH (R01 AG011378, P50 AG016574, U01 AG006786, AG029550, AG032306, and U01 HL096917). R.C.P. serves on scientific advisory boards for Roche, Inc., Merck, Inc., Biogen, Inc., and Genentech, Inc.; receives royalties from the publication of Mild Cognitive Impairment (Oxford University Press, 2003); and receives research support from the National Institutes of Health (P50 AG016574, U01 AG006786, U01 AG024904, and R01 AG011378). M.M.Mi. served as a consultant to Eli Lilly and Lysosomal Therapeutics, Inc., and receives research support from the National Institutes of Health (R01 AG49704, P50 AG44170, U01 AG06786, and RF1 AG55151), Department of Defense (W81XWH-15-1), and unrestricted research grants from Biogen and Lundbeck.
Publisher Copyright:
© 2018 The Author(s) 2018. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
PY - 2019/7/12
Y1 - 2019/7/12
N2 - Background: Chronic inflammation has been linked with geriatric-related conditions, including dementia. Inflammatory cytokine levels, including interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF) α, in the blood have been associated with cognitive impairment and decline. However, evidence has been mixed. Methods: We examined the cross-sectional and longitudinal associations between baseline-measured IL-6, IL-10, and TNFα levels and the ratio of IL-6/IL-10 with cognitive test performance and mild cognitive impairment (MCI) among 1,602 community-dwelling older adults (median age = 72.8) enrolled in the Mayo Clinic Study of Aging. Approximately half (46.5%) of participants were female and 98.6% were white. At baseline and follow-up visits (occurring at 15-month intervals), participants completed neuropsychological testing, blood draws, and had a clinical consensus diagnosis. Results: In multivariable cross-sectional analyses, we did not observe an association between inflammatory cytokine levels and global or domain-specific cognitive z scores; however, higher IL-6 and IL-10 levels were associated with greater odds of a MCI diagnosis. Longitudinally, we did not observe any association between inflammatory cytokine levels and cognitive test performance or risk of MCI. Sex, age, cognitive status, APOE ϵ4 genotype, diabetes, depression, and cerebral amyloid-beta deposition were not effect modifiers. Conclusions: These results suggest that plasma inflammatory markers may not be useful to ascertain risk for cognitive decline and MCI in the general population.
AB - Background: Chronic inflammation has been linked with geriatric-related conditions, including dementia. Inflammatory cytokine levels, including interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF) α, in the blood have been associated with cognitive impairment and decline. However, evidence has been mixed. Methods: We examined the cross-sectional and longitudinal associations between baseline-measured IL-6, IL-10, and TNFα levels and the ratio of IL-6/IL-10 with cognitive test performance and mild cognitive impairment (MCI) among 1,602 community-dwelling older adults (median age = 72.8) enrolled in the Mayo Clinic Study of Aging. Approximately half (46.5%) of participants were female and 98.6% were white. At baseline and follow-up visits (occurring at 15-month intervals), participants completed neuropsychological testing, blood draws, and had a clinical consensus diagnosis. Results: In multivariable cross-sectional analyses, we did not observe an association between inflammatory cytokine levels and global or domain-specific cognitive z scores; however, higher IL-6 and IL-10 levels were associated with greater odds of a MCI diagnosis. Longitudinally, we did not observe any association between inflammatory cytokine levels and cognitive test performance or risk of MCI. Sex, age, cognitive status, APOE ϵ4 genotype, diabetes, depression, and cerebral amyloid-beta deposition were not effect modifiers. Conclusions: These results suggest that plasma inflammatory markers may not be useful to ascertain risk for cognitive decline and MCI in the general population.
KW - Epidemiology
KW - Inflammation
KW - Mild cognitive impairment
UR - http://www.scopus.com/inward/record.url?scp=85062955355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062955355&partnerID=8YFLogxK
U2 - 10.1093/gerona/gly217
DO - 10.1093/gerona/gly217
M3 - Article
C2 - 30256904
AN - SCOPUS:85062955355
VL - 74
SP - 1289
EP - 1295
JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences
JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences
SN - 1079-5006
IS - 8
M1 - gly217
ER -